Effect of Probucol Combined with Rosuvastatin on Endothelial Cell Function and Serum Hepcidin-25 Levels in Patients with Ischemic Stroke
Objective:To investigate the effects of probucol combined with rosuvastatin on endothelial cell function and serum hepcidin-25(Hepc25)level in patients with ischemic stroke(IS).Methods:A total of 130 patients with IS who were treated in a hospital from May 2020 to April 2023 were selected and divided into control group and observation group by random number table method,with 65 patients in each group.The patients were given conventional treatment based on their conditions,including blood pressure management,temperature control,respiration support,glucose control,thrombolysis,anticoagulation,antiplatelet therapy,neuroprotection and intracranial pressure control.The control group was given rosuvastatin calcium tablets in addition to the conventional treatment,and the observation group was given probucol tablets in addition to the treatment received by the control group.Both groups were treated for 6 months.The clinical efficacy,neurological function[National Institute of Health stroke scale(NIHSS),Barthel index(BI)and Montreal cognitive assessment(MoCA)],endothelial cell function[vascular endothelial growth factor(VEGF),stromal cell-derived factor-1 α(SDF-1α),angiopoietin(Ang)and platelet-derived growth factor(PDGF)],serum Hepc25 levels and the incidence of adverse reactions were compared between the two groups.Results:Following treatment,the overall treatment effectiveness in the observation group(93.85%)was higher than that of the control group(73.85%,P<0.05).The NIHSS scores and serum Hepc25 level were decreased in both groups,and the observation group were lower than those in the control group(P<0.05).BI,MoCA scores,and the levels of VEGF,SDF-1α,Ang and PDGF were increased in both groups,and the observation group were higher than those in the control group(P<0.05).No statistically significant difference was observed in the overall incidence of adverse reactions during the treatment period between the two groups(P>0.05).Conclusion:Probucol in combination with rosuvastatin demonstrated significant clinical efficacy in the treatment of IS patients when added to the conventional treatment.This combined treatment can effectively improve the condition of IS patients and the function of endothelial cells,reduce the serum Hepc25 levels,and does not increase the risk of adverse reactions.
万方数据
维普
